Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biomira Truquant BR approval pending January 1996 FDA premarket inspection.

This article was originally published in The Gray Sheet

Executive Summary

BIOMIRA TRUQUANT BR CLEARANCE AWAITS FDA PREAPPROVAL INSPECTION slated for January 1996, the company says. Biomira has "completed all conditions" spelled out by FDA in a recent approvable letter for the premarket approval application for Truquant BR, a blood test intended for use as an "independent predictor of recurrence of breast cancer in women with Stage II and Stage III disease," the company said in a Dec. 14 press release. The only remaining hurdle to approval is a successful inspection of its manufacturing facilities in Toronto.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts